替罗非班以及不同给药途径对AMI患者PCI术后sICAM-1的影响

探讨替罗非班以及不同给药途径对急性心肌梗死（AMI）患者经皮冠状动脉介入术（PCI）后可溶性细胞间粘附因子-1（sICAM-1）的影响.选择AMI直接PCI患者90例随机分成A、B、C三组：A组不给予替罗非班;B组PCI术后静脉给予替罗非班,C组PCI术中对梗死相关冠状动脉（IRA）内注射替罗非班,两组均静脉滴注36h;分别检测三组术前及术后24h血浆sICAM-1的浓度水平.结果显示,A组PCI术后24h血浆sICAM-1的浓度水平较术前高,而B、C两组较术前均降低,差异有统计学意义（P＆lt;0.05）,但B、C两组PCI术后差异无统计学意义（P＞0.05）.因此,对于行PCI术的AMI患者应给予替罗非班,抑制术后炎症反应以及粘附反应,降低PCI术后再狭窄的发生率,但其作用效果与给药途径无关.

The Effects of Tirofiban and Different Administration of Tirofiban on Level of sICAM-1 in Acute Myocardial Infarction Patients after Percutaneous Coronary Intervention

To explore the effects of tirofiban and different administration of tirofiban on level of sICAM-- 1 in acute myocardial infarction （AMI） patients after pereutaneous coronary intervention （PCI）. 90 patients with AMI undergoing PCI were randomly divided into group A, group B and group C. Group A did not receive tirofiban neither via intracoronary （IC） nor intravenous （IV） route. Group B after PCI received tirofiban via IV route, Group C during PCI received tirofiban via IC route and both of them were followed by a 36 hours of IV infusion. The plasma levels of slCAM-- 1 before PCI and 24 hours after PCI were measured. The result showed that the postoperative plasma levels of sICAM-- 1 of Group A increased compared with the preoperative levels and the difference was statistically significant （P%0.05）, which was iust opposite with Group B and Group C. There were no significant differences between Group B and Group C（P~〉0.05）. Therefore, the influence of tirofiban for sICAM--1 of AMI patients treated with PCI is obvious and the effect is independent with the route of administration.